---
title: "688621.SH (688621.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688621.SH/news.md"
symbol: "688621.SH"
name: "688621.SH"
parent: "https://longbridge.com/en/quote/688621.SH.md"
datetime: "2026-05-20T10:15:18.420Z"
locales:
  - [en](https://longbridge.com/en/quote/688621.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688621.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688621.SH/news.md)
---

# 688621.SH (688621.SH) — Related News

### [Sun-Novo plans to increase its subsidiary's capital by 70 million yuan to create a peptide drug research and development platform centered on AI technology](https://longbridge.com/en/news/286566158.md)
*2026-05-15T12:33:02.000Z*
> Sun-Novo plans to increase its investment in its wholly-owned subsidiary Guangdong Novo Peptide Biotechnology Co., Ltd. 

### [Sun-Novo: Currently advancing overseas cooperation negotiations in an orderly manner based on pipeline progress](https://longbridge.com/en/news/284170613.md)
*2026-04-27T07:44:00.000Z*
> Sun-Novo stated today on the interactive platform that the company is steadily advancing overseas cooperation negotiatio

### [Sun-Novo: Signed a supplementary agreement for STC008 injection with Yatai pharm](https://longbridge.com/en/news/283959502.md)
*2026-04-24T08:22:54.000Z*
> Sun-Novo signed a supplementary agreement for the STC008 injection with Zhejiang Xinghao Holdings and Zhejiang Yatai Pha

### [Sun-Novo: Net profit of 20.631 million yuan in the first quarter of 2026, a year-on-year decrease of 30.25%](https://longbridge.com/en/news/283849560.md)
*2026-04-23T14:04:28.000Z*
> Sun-Novo announced that its revenue for the first quarter of 2026 was 197 million yuan, a year-on-year decrease of 14.62

### [Sun-Novo signed a research and development agreement for the antibacterial innovative drug IMB0304 with WuXi AppTec](https://longbridge.com/en/news/282496789.md)
*2026-04-13T06:40:44.000Z*
> On April 10, 2026, Sun-Novo officially signed a research and development cooperation agreement for the antibacterial inn

### [Sun-Novo: ABA001 injection has received approval for clinical trials](https://longbridge.com/en/news/281487118.md)
*2026-04-02T08:03:02.000Z*
> Sun-Novo and its wholly-owned subsidiary Beijing Arna Technology Co., Ltd. have received approval from the National Medi

### [Sun-Novo: Signed a technology licensing and cooperation development agreement with Salubris for the joint development of the STC007 injection project](https://longbridge.com/en/news/279921897.md)
*2026-03-20T10:01:27.000Z*
> Sun-Novo and Salubris signed a technology licensing and cooperation development agreement to jointly develop the STC007